The neutrophil-to-lymphocyte ratio at the start of the second course during atezolizumab plus bevacizumab therapy predicts therapeutic efficacy in patients with advanced hepatocellular carcinoma: A multicenter analysis.
Sho MatoyaTakanori SuzukiKentaro MatsuuraYuta SuzukiFumihiro OkumuraYoshihito NaguraSatoshi SobueKeita KuroyanagiAtsunori KusakabeHiroki KoguchiIzumi HasegawaTomokatsu MiyakiYoshito TanakaHiromu KondoYoshihide KimuraAtsushi OzasaHayato KawamuraKayoko KunoKei FujiwaraShunsuke NojiriHiromi Kataokanull nullPublished in: Hepatology research : the official journal of the Japan Society of Hepatology (2023)
The NLR-2c value predicts the initial therapeutic response and prognosis of patients with HCC treated with Atez/Bev therapy.